FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS NOT ADEQUATELY CONTROLLED WITH INHALED CORTICOSTEROIDS AND INHALED SHORT ACTING BETA2-AGONISTS: A BUDGET IMPACT ANALISYS IN ITALY

被引：0

作者：

Mangia, P. P. ^{[1
]}

Pradelli, L. ^{[1
]}

Gallo, O. ^{[2
]}

Ritrovato, D. ^{[2
]}

Ting, B. ^{[3
]}

机构：

[1] AdRes HEOR, Turin, TO, Italy

[2] Novartis Farma Italy, Origgio, Italy

[3] Novartis Corp Sdn Bhd, Petaling Jaya, Malaysia

来源：

VALUE IN HEALTH | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PRS39

引用

页码：S724 / S724

页数：1

共 11 条

[1] COST-UTILITY ANALYSIS OF FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS NOT ADEQUATELY CONTROLLED WITH INHALED CORTICOSTEROIDS AND INHALED SHORT ACTING BETA2-AGONISTS
Mangia, P. P.
Pradelli, L.
Gallo, O.
Ritrovato, D.
Gupta, S.
VALUE IN HEALTH, 2020, 23 : S721 - S722
[2] Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studies
Buhl, Roland
Kerstjens, Huib
Nikolaev, Ivan
Vaidya, Soniya
Bartels, Christian
Jain, Monish
Jauernig, Juergen
Kottakis, Ioannis
Qian, Chenyu
Tillman, Hanns-Christian
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB59 - AB59
[3] COST-UTILITY ANALYSIS OF FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) GLYCOPYRRONIUM BROMIDE (GLY) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT IN ADULT ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED WITH A MAINTENANCE COMBINATION OF A LONG-ACTING BETA2-AGONIST AND A HIGH DOSE OF AN INHALED CORTICOSTEROID WHO EXPERIENCED ONE OR MORE ASTHMA EXACERBATIONS IN THE PREVIOUS YEAR
Mangia, P. P.
Pradelli, L.
Gallo, O.
Ritrovato, D.
Gupta, S.
VALUE IN HEALTH, 2020, 23 : S719 - S719
[4] Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year
Pier Paolo Mangia
Ottavio Gallo
Daniela Ritrovato
Lorenzo Pradelli
Clinical Drug Investigation, 2021, 41 : 785 - 794
[5] Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year
Mangia, Pier Paolo
Gallo, Ottavio
Ritrovato, Daniela
Pradelli, Lorenzo
CLINICAL DRUG INVESTIGATION, 2021, 41 (09) : 785 - 794
[6] Which Therapeutic Option is the Safest for the Fetus in the Treatment of Maternal Asthma: Higher Dose Inhaled Corticosteroids or Long-Acting beta2-Agonists Plus Lower Dose Inhaled Corticosteroids?
Eltonsy, Sherif
Forget, Amelie
Beauchesne, Marie-France
Blais, Lucie
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 149 - 150
[7] Both once-daily (QD) and twice-daily (BID) mometasone furoate (MF) provide additional improvement in patients previously maintained on short-acting inhaled beta2-agonists
Kemp, JP
Stewart, GE
Ruff, ME
Murray, JJ
Harrison, JE
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (01) : U4 - U4
[8] Impact of Omalizumab Initiation on Emergency-Department Visits, Hospitalizations and Corticosteroid Use in Patients with Uncontrolled Asthma Using High-Dose Inhaled Corticosteroids and Long-Acting Beta2-Agonists
Lafeuille, Marie-Helene
Dean, Jason
Zhang, Jie
Duh, Mei Sheng
Gorsh, Boris
Lefebvre, Patrick
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 21 - 21
[9] Safety and Tolerability of Medium and High Doses of Mometasone Furoate/Formoterol (MF/F) Combination Treatment, Administered Via a Metered-Dose Inhaler (MDI), in Severe Asthma Patients Previously Treated with High-Dose Inhaled Corticosteroids (ICS).
Weinstein, S. F.
White, M.
Corren, J.
Nolte, H.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
[10] Single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis
Rodriguez-Martinez, Carlos E.
Sossa-Briceno, Monica P.
Castro-Rodriguez, Jose A.
JOURNAL OF ASTHMA, 2025, 62 (03) : 500 - 507

← 1 2 →